ERBB2 and neoplasm: HER2-targeted PET imaging with radiolabeled antibodies and antibody fragments has demonstrated the ability to help select patients that may best benefit from HER2-targeted therapies [198–204], even among patients with tumours previously presumed to lack HER2 expression [205].